However, the clinical potential of classical TZD-based PPAR agonists is limited with rosiglitazone having been withdrawn from clinical use in Europe due to its cardiovascular toxicity and pioglitazone being banned in Germany and France due to an associated risk for the development of bladder cancer [17]. The gene discussed is PPARA; the disease is urinary bladder carcinoma.